OncoCyte Corporation
OCX
$2.88
$0.041.41%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -109.55% | -107.94% | 45.64% | -400.99% | 64.44% |
| Total Depreciation and Amortization | 73.23% | -20.19% | -28.67% | -29.03% | -74.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 144.64% | 248.65% | -122.43% | 140.09% | -65.07% |
| Change in Net Operating Assets | -127.25% | -101.77% | 26.72% | 151.86% | -225.31% |
| Cash from Operations | -21.02% | -47.28% | 12.50% | 53.86% | 54.15% |
| Capital Expenditure | 18.94% | -411.76% | -- | -- | 67.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -303.88% | -140.65% | -255.28% | 98.25% | 112.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -173.33% | -186.67% | -13.79% | -- | 70.00% |
| Issuance of Common Stock | -- | -- | 14.15% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -382.02% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -26.00% | -- | -- |
| Cash from Financing | 36,223.33% | -750.00% | -19.77% | -- | 70.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 221.19% | -64.38% | -33.91% | 60.27% | 58.76% |